Conference Coverage

VIDEO: Salvageable brain tissue can guide decision for stroke thrombectomy


AT ANA 2017

SAN DIEGO – Neurologists have long suspected that some stroke patients could benefit from thrombectomy many hours after they were last seen well. But lingering doubts remained, and physicians weren’t sure which stroke patients were likely to improve.

At the European Stroke Organization Conference in May, Stryker Neurovascular announced the results of its DAWN trial, which tested the company’s mechanical thrombectomy device in patients who’d suffered a stroke within the past 6-24 hours and in whom imaging showed a clinical core mismatch. It was stopped early based on an interim analysis after it met multiple prespecified stopping criteria. At 90 days, 48.6% of patients in the treatment group were functionally independent, compared with 13.1% who received only medical management.

The DEFUSE 3 trial examined endovascular thrombectomy in patients 6-16 hours after a stroke who appeared to have salvageable brain tissue based on target mismatch profile with a less extreme core than in DAWN. It too was halted early because of a high probability of efficacy. Together, the trials suggest neurologists are entering a new era of treating based on tissue and not just time, Dr. Saver said.

Vidyard Video

Recommended Reading

Higher stroke risk found for TAVR versus SAVR
MDedge Cardiology
Young adult stroke survivors have distinct risk profile
MDedge Cardiology
Eye movement, not CT or MRI, rules out posterior stroke
MDedge Cardiology
MI, stroke risk from HFrEF surpasses HFpEF
MDedge Cardiology
VIDEO: Mobile stroke units aren’t just expensive toys
MDedge Cardiology

Related Articles